Anti-D Rho immunoglobulin - Bharat Serums and Vaccines

Drug Profile

Anti-D Rho immunoglobulin - Bharat Serums and Vaccines

Alternative Names: Anti-D immunoglobulin (monoclonal); Rhoclone

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Bharat Serums and Vaccines
  • Class Immunoglobulins
  • Mechanism of Action Immunoglobulin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemolytic disease of newborn

Most Recent Events

  • 31 Aug 2016 Launched for Haemolytic disease of newborn (Prevention, In neonates) in India (IM) before August 2016 (Bharat Serums ans Vaccines Pipeline, August 2016)
  • 31 Aug 2016 Bharat Serums ans Vaccines plans a phase III trial for Hemolytic disease of newborn in India (CTRI2015-09-006172)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top